March 5, 2026 USA
SACC-SF highlights Diamyd Medical in member deep dive
In a member deep dive by the Swedish American Chamber of Commerce in San Francisco & Silicon Valley (SACC-SF), board member Dr. Karin Rosén discusses Diamyd Medical’s precision medicine approach for type 1 diabetes. The article highlights the company’s ongoing Phase 3 clinical trial in the United States and Europe evaluating an antigen-specific immunotherapy designed to preserve patients’ own insulin production. Dr. Rosén also comments on the importance of regulatory dialogue with the FDA and long-term planning for access to the U.S. market.
Read the interview here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.